RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Axsome Therapeutics Stock

Axsome Therapeutics Market capitalization 2024

Axsome Therapeutics Market capitalization

4.07 B USD

Ticker

AXSM

ISIN

US05464T1043

WKN

A2AA7B

In 2024, Axsome Therapeutics's market cap stood at 4.07 B USD, a 30.25% increase from the 3.13 B USD market cap in the previous year.

The Axsome Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
20233.19
20221.76
20212.09
20202.89
20190.82
20180.08
20170.11
20160.16
20150.11
2014-
2013-

Axsome Therapeutics Aktienanalyse

What does Axsome Therapeutics do?

Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of severe psychiatric and neurological disorders. The company was founded in 2012 and is headquartered in New York City. The history of Axsome Therapeutics began with the identification of a new molecule called AXS-05, which was developed as a potential antidepressant and treatment for Alzheimer's disease. The company utilized its proprietary technology platform to optimize the drug's properties and then began conducting clinical studies to evaluate the efficacy and safety of AXS-05 in patients with depression, Alzheimer's disease, and other neurological disorders. Axsome Therapeutics' business model is based on the identification and development of novel drug candidates through the use of knowledge about novel target molecules and innovative technologies. The company aims to rapidly and cost-effectively develop its drugs to quickly achieve commercial benefits from its developments. The company relies on collaboration with strategic partners and acquisitions for faster market entry. Axsome Therapeutics is divided into several business areas, each identifying and developing different drug candidates. For example, one area is the field of pain medicine, where the company is developing novel therapies for chronic pain and migraines. Another area is psychiatric disorders, where the company focuses on novel treatments for depression, anxiety disorders, bipolar disorder, and post-traumatic stress disorder. A third area is neurodegenerative diseases, where the company is researching new approaches to treating Alzheimer's disease and Parkinson's disease. Axsome Therapeutics has several products in the pipeline at various stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III clinical trials for the treatment of depression and Alzheimer's disease. AXS-05 has been deemed safe and well-tolerated in previous studies and has shown significant improvement in symptoms in patients with severe depression. In studies on Alzheimer's and dementia, the medication showed preliminary improvement in specific disease symptoms. In addition to AXS-05, the company is also working on the development of AXS-12, a drug for the treatment of narcolepsy, and AXS-09, a combination of two known drugs for the treatment of migraines. In summary, Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of severe psychiatric and neurological disorders. The company has developed a proprietary technology platform that allows for cost-effective optimization and rapid development of drug candidates. Axsome Therapeutics is divided into several business areas and has several products in the pipeline at different stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III trials for the treatment of depression and Alzheimer's disease. Axsome Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Axsome Therapeutics's Market Capitalization

Axsome Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Axsome Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Axsome Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Axsome Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Axsome Therapeutics stock

What is the current Axsome Therapeutics market capitalization?

The current market capitalization of Axsome Therapeutics is 4.07 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Axsome Therapeutics.

How has the market capitalization of Axsome Therapeutics developed in recent years?

The market capitalization of Axsome Therapeutics has increased/decreased by 30.25% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Axsome Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Axsome Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Axsome Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Axsome Therapeutics pay?

Over the past 12 months, Axsome Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Axsome Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Axsome Therapeutics?

The current dividend yield of Axsome Therapeutics is .

When does Axsome Therapeutics pay dividends?

Axsome Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Axsome Therapeutics?

Axsome Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Axsome Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Axsome Therapeutics located?

Axsome Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Axsome Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Axsome Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Axsome Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Axsome Therapeutics in the year 2023?

In the year 2023, Axsome Therapeutics distributed 0 USD as dividends.

In which currency does Axsome Therapeutics pay out the dividend?

The dividends of Axsome Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Axsome Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Axsome Therapeutics

Our stock analysis for Axsome Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Axsome Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.